Safety and effectiveness of daily teriparatide in a prospective observational study in patients with osteoporosis at high risk of fracture in Japan: final report

Safety and effectiveness of daily teriparatide in a prospective observational study in patients with osteoporosis at high risk of fracture in Japan: final report

Atsushi Nishikawa,1 Takehiro Ishida,2 Masanori Taketsuna,3 Fumito Yoshiki,4 Hiroyuki Enomoto4 1Global Patient Safety Japan, Quality and Patient Safety, 2Clinical Development Operations and Innovations, Medicine Development Unit Japan, 3Asia Pacific Statistical Sciences, Medicine Development Unit Ja...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Nishikawa A, Ishida T, Taketsuna M, Yoshiki F, Enomoto H
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2016
Materias:
Keywords Parathyroid Hormone
Bone Biomarkers
Bone Mineral Density
Quality of Life
Safety
Geriatrics
RC952-954.6
Acceso en línea:https://doaj.org/article/9996dc25b2484733841c870dadcc4c90
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:9996dc25b2484733841c870dadcc4c90
record_format dspace
spelling oai:doaj.org-article:9996dc25b2484733841c870dadcc4c902021-12-02T07:48:51ZSafety and effectiveness of daily teriparatide in a prospective observational study in patients with osteoporosis at high risk of fracture in Japan: final report1178-1998https://doaj.org/article/9996dc25b2484733841c870dadcc4c902016-07-01T00:00:00Zhttps://www.dovepress.com/safety-and-effectiveness-of-daily-teriparatide-in-a-prospective-observ-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Atsushi Nishikawa,1 Takehiro Ishida,2 Masanori Taketsuna,3 Fumito Yoshiki,4 Hiroyuki Enomoto4 1Global Patient Safety Japan, Quality and Patient Safety, 2Clinical Development Operations and Innovations, Medicine Development Unit Japan, 3Asia Pacific Statistical Sciences, Medicine Development Unit Japan, 4Medical Sciences, Medicines Development Unit Japan, Eli Lilly Japan K.K., Kobe, Japan Abstract: This postmarketing surveillance study assessed the safety and effectiveness of teriparatide in patients with osteoporosis at high risk of fracture in Japan. The patients received teriparatide 20 µg daily by subcutaneous injection, for a maximum of 24 months. Safety and effectiveness analyses were based on data from 1,847 patients who were predominantly female (92.6%) with a mean age of 75.4 years. A total of 157 adverse drug reactions (ADRs) were reported in 140 (7.58%) patients; the most common ADRs were hyperuricemia, nausea, and dizziness. Only six (0.32%) patients reported serious ADRs, the most common being nausea (two patients; 0.1%). Persistence with teriparatide treatment was 60.8% and 39.1% at 18 and 24 months, respectively. There were significant increases in biomarkers for bone formation (procollagen type I N-terminal propeptide and bone-specific alkaline phosphatase) and bone resorption (collagen type I cross-linked C telopeptide and tartrate-resistant acid phosphatase 5b) throughout the study. These were accompanied by significant increases in bone mineral density and low incidences of new vertebral and nonvertebral fractures. Patient-reported measurements for health-related quality of life revealed significant improvements from baseline in back pain and overall health-related quality of life (Short Form-8™ health survey). The results of this 24-month postmarketing surveillance study imply that teriparatide has a favorable safety profile and is effective in the treatment of patients with osteoporosis at high risk of fracture in Japan. Teriparatide may also be a useful treatment for osteoporosis in other societies with aging populations. Keywords: parathyroid hormone, bone biomarkers, bone mineral density, quality of life, safetyNishikawa AIshida TTaketsuna MYoshiki FEnomoto HDove Medical PressarticleKeywords Parathyroid HormoneBone BiomarkersBone Mineral DensityQuality of LifeSafetyGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 11, Pp 913-925 (2016)
institution DOAJ
collection DOAJ
language EN
topic Keywords Parathyroid Hormone
Bone Biomarkers
Bone Mineral Density
Quality of Life
Safety
Geriatrics
RC952-954.6
spellingShingle Keywords Parathyroid Hormone
Bone Biomarkers
Bone Mineral Density
Quality of Life
Safety
Geriatrics
RC952-954.6
Nishikawa A
Ishida T
Taketsuna M
Yoshiki F
Enomoto H
Safety and effectiveness of daily teriparatide in a prospective observational study in patients with osteoporosis at high risk of fracture in Japan: final report
description Atsushi Nishikawa,1 Takehiro Ishida,2 Masanori Taketsuna,3 Fumito Yoshiki,4 Hiroyuki Enomoto4 1Global Patient Safety Japan, Quality and Patient Safety, 2Clinical Development Operations and Innovations, Medicine Development Unit Japan, 3Asia Pacific Statistical Sciences, Medicine Development Unit Japan, 4Medical Sciences, Medicines Development Unit Japan, Eli Lilly Japan K.K., Kobe, Japan Abstract: This postmarketing surveillance study assessed the safety and effectiveness of teriparatide in patients with osteoporosis at high risk of fracture in Japan. The patients received teriparatide 20 µg daily by subcutaneous injection, for a maximum of 24 months. Safety and effectiveness analyses were based on data from 1,847 patients who were predominantly female (92.6%) with a mean age of 75.4 years. A total of 157 adverse drug reactions (ADRs) were reported in 140 (7.58%) patients; the most common ADRs were hyperuricemia, nausea, and dizziness. Only six (0.32%) patients reported serious ADRs, the most common being nausea (two patients; 0.1%). Persistence with teriparatide treatment was 60.8% and 39.1% at 18 and 24 months, respectively. There were significant increases in biomarkers for bone formation (procollagen type I N-terminal propeptide and bone-specific alkaline phosphatase) and bone resorption (collagen type I cross-linked C telopeptide and tartrate-resistant acid phosphatase 5b) throughout the study. These were accompanied by significant increases in bone mineral density and low incidences of new vertebral and nonvertebral fractures. Patient-reported measurements for health-related quality of life revealed significant improvements from baseline in back pain and overall health-related quality of life (Short Form-8™ health survey). The results of this 24-month postmarketing surveillance study imply that teriparatide has a favorable safety profile and is effective in the treatment of patients with osteoporosis at high risk of fracture in Japan. Teriparatide may also be a useful treatment for osteoporosis in other societies with aging populations. Keywords: parathyroid hormone, bone biomarkers, bone mineral density, quality of life, safety
format article
author Nishikawa A
Ishida T
Taketsuna M
Yoshiki F
Enomoto H
author_facet Nishikawa A
Ishida T
Taketsuna M
Yoshiki F
Enomoto H
author_sort Nishikawa A
title Safety and effectiveness of daily teriparatide in a prospective observational study in patients with osteoporosis at high risk of fracture in Japan: final report
title_short Safety and effectiveness of daily teriparatide in a prospective observational study in patients with osteoporosis at high risk of fracture in Japan: final report
title_full Safety and effectiveness of daily teriparatide in a prospective observational study in patients with osteoporosis at high risk of fracture in Japan: final report
title_fullStr Safety and effectiveness of daily teriparatide in a prospective observational study in patients with osteoporosis at high risk of fracture in Japan: final report
title_full_unstemmed Safety and effectiveness of daily teriparatide in a prospective observational study in patients with osteoporosis at high risk of fracture in Japan: final report
title_sort safety and effectiveness of daily teriparatide in a prospective observational study in patients with osteoporosis at high risk of fracture in japan: final report
publisher Dove Medical Press
publishDate 2016
url https://doaj.org/article/9996dc25b2484733841c870dadcc4c90
work_keys_str_mv AT nishikawaa safetyandeffectivenessofdailyteriparatideinaprospectiveobservationalstudyinpatientswithosteoporosisathighriskoffractureinjapanfinalreport
AT ishidat safetyandeffectivenessofdailyteriparatideinaprospectiveobservationalstudyinpatientswithosteoporosisathighriskoffractureinjapanfinalreport
AT taketsunam safetyandeffectivenessofdailyteriparatideinaprospectiveobservationalstudyinpatientswithosteoporosisathighriskoffractureinjapanfinalreport
AT yoshikif safetyandeffectivenessofdailyteriparatideinaprospectiveobservationalstudyinpatientswithosteoporosisathighriskoffractureinjapanfinalreport
AT enomotoh safetyandeffectivenessofdailyteriparatideinaprospectiveobservationalstudyinpatientswithosteoporosisathighriskoffractureinjapanfinalreport
_version_ 1718399175434960896

Ejemplares similares